Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Efectivamente, se han blindado ante una posible adquisición (cambio de control). No de una forma abusiva (12-18 meses de salario + bonus) y, si, es habitual (en USA... y en todas partes)
El resto son subidas de sueldo, bonus, reparto de stock options... si a alguno le parecen excesivos que piense lo que se han auto-otorgado aquí los directivos de muchas cajas por arruinarlas. Estos, al menos están sacando una empresa adelante. Y, cuanto más ganen por sus stock options, más ganamos todos
S2
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
mira que he tenido tentaciones, pero no le he mandado ni un solo privado.
Es una persona que vale muchisimo y ya dejo claro que mejor que no se le sobrecargara.
Si de vez en cuando se quisiera pasar por aquí, nos vendría fenomenal :-)
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
noticias frescas creo(por lo menos nuevas en la web de origen), os lo pongo por si puede ser interesante
http://www.4-traders.com/THRESHOLD-PHARMACEUTICALS-4706838/news/THRESHOLD-PHARMACEUTICALS-INC-Threshold-Pharmaceuticals-Announces-Presentation-and-Webcast-at-Bi-14271112/
___________________
Threshold Pharmaceuticals, Inc. : Threshold Pharmaceuticals Announces Presentation and Webcast at BioCentury Future Leaders Conference
04/13/2012 | 08:27am
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/13/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Chief Executive Officer of Threshold, is scheduled to present at the 19th Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 20, at 10:30 a.m. Eastern time in New York City.
A live webcast of the presentation will be available under Webcasts in the Investors section of www.thresholdpharm.com. A replay of the presentation will be archived on the site for 90 days.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.www.thresholdpharm.com).
Contact:
Joel A. Fernandes
Threshold Pharmaceuticals, Inc.
650.474.8273
_________________